Social Media Ideas for Companion Diagnostics

FDA Eases Approval Path for Certain Cancer Companion Diagnostic Tests

The U.S. Food and Drug Administration has issued a final order moving certain laboratory tests used to help guide treatment with approved cancer drugs from...

Labcorp nabs FDA green light for BRAF melanoma diagnostic

The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.

Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay

Diagnostics specialist Beckman Coulter expanded its portfolio of Alzheimer’s disease diagnostics by earning a CE mark in Europe for its Access p-Tau217 assay.

The Rise of Consumer Diagnostics and Emerging Trends

Consumer diagnostics will be one of several discussions at the INVEST Digital Health conference focused on power shifting to the consumer in healthcare. The conference is scheduled...

Caris Life Sciences launches cancer blood test ‘Caris Detect’

Caris Life Sciences has launched a new oncology blood test designed alongside AI modelling to pick up cancer at earlier stages.

Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseases

Labcorp is launching the Marker by Labcorp Genetic Health Panel, a new direct-to-consumer genetic testing tool that analyzes 163 genes to determine patients’ risk of over 100 hered...

A genome-first multiomic approach to diagnosis

Did you know that one in 10 Americans have a rare disease and it can take five or more years, on average, for a person with a rare disease to get an accurate diagnosis? That’s more...

<![CDATA[FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study ]]>

<![CDATA[FDA Clears Consano’s IND for C-1101 ]]>

<![CDATA[FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay ]]>

Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUSâ„¢, the Fir...

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's r...

AI Tool Enhances Accuracy in Predicting Patient Response to Cancer Immunotherapy Drugs

In the relentless pursuit of personalized cancer treatment, a groundbreaking artificial intelligence (AI) model named COMPASS is setting a new standard in predicting patient respon...

<![CDATA[BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies ]]>

Partnership with Oxford Nanopore Technologies will support development of RNA liquid biopsy for cancer early detection

RNA sequencing and nanopore sequencing enabled Eclipse-like full transcriptome analysis to identify novel non-coding RNA biomarkers in extracellular vesicles for early esophageal.....

Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis

Personalis’s liquid biopsy is part of a growing market for minimal residual disease assays, tests that look for any remaining cancer cells after the initial treatment. Tempus AI ha...